Quince Therapeutics (QNCX) Net Income (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Net Income of $35.9 million for Q1 2026, up 338.94% year-over-year from $8.2 million in Q1 2025, and up 286.24% quarter-over-quarter from -$19.3 million in Q4 2025.
Quince Therapeutics (QNCX) Net Income (2018 - 2026) Analysis & Trends
Quince Therapeutics' Net Income history runs 9 years deep, the most recent figure standing at $35.9 million for Q1 2026.
- In Q1 2026, Net Income rose 338.94% year-over-year to $35.9 million; the TTM figure through Mar 2026 stood at -$12.9 million (up 78.81% YoY), while the FY2025 annual figure was -$63.8 million, down 12.28% from the prior year.
- Net Income for Q1 2026 stood at $35.9 million, up from -$19.3 million in the prior quarter.
- The five-year high for Net Income was $35.9 million in Q1 2026, with the low at -$27.7 million in Q2 2024.
- The 5-year median for Net Income is -$12.3 million (2023), against an average of -$9.9 million.
- The sharpest annual moves came in 2024 and 2026: Net Income tumbled 467.52% in 2024, then jumped 338.94% in 2026.
- Quince Therapeutics' Net Income stood at -$5.5 million in 2022, then slumped by 60.72% to -$8.9 million in 2023, then tumbled by 40.07% to -$12.5 million in 2024, then sank by 54.78% to -$19.3 million in 2025, then jumped by 286.24% to $35.9 million in 2026.
- Business Quant data shows QNCX's Net Income at $35.9 million in Q1 2026, -$19.3 million in Q4 2025, and -$13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | -75.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.91 Mn |
| Dec 31, 2025 | -19.28 Mn |
| Sep 30, 2025 | -13.44 Mn |
| Jun 30, 2025 | -16.05 Mn |
| Mar 31, 2025 | -15.03 Mn |
| Dec 31, 2024 | -12.46 Mn |
| Sep 30, 2024 | -5.49 Mn |
| Jun 30, 2024 | -27.73 Mn |
| Mar 31, 2024 | -11.15 Mn |
| Dec 31, 2023 | -8.89 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -4.89 Mn |
| Mar 31, 2023 | -12.25 Mn |
| Dec 31, 2022 | -5.53 Mn |
| Sep 30, 2022 | -7.92 Mn |
| Jun 30, 2022 | -16.56 Mn |
| Mar 31, 2022 | -21.64 Mn |
| Dec 31, 2021 | 66.55 Mn |
| Sep 30, 2021 | -21.71 Mn |
| Jun 30, 2021 | -21.75 Mn |